Colleen Sjogren
Vermögen: 559 440 $ am 31.08.2026
Vermögen: 559 440 $ am 31.08.2026
Ms. Colleen Sjogren is a Chief Commercial Officer at Nuvation Bio, Inc. Ms. Sjogren was previously employed as a Senior Vice President-Sales by Madrigal Pharmaceuticals, Inc., a VP-US Sales, Sales Training & Meeting Planning by Mirati Therapeutics, Inc., and a Vice President-National Cell Therapy & Sales by Kite Pharma, Inc. She received her undergraduate degree from Bryant University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 27.02.2026 | 84’000 ( 0.02% ) | 559 440 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| NUVATION BIO INC. | Corporate Officer/Principal | 28.03.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Vertrieb & Marketing | 01.12.2023 |
| MIRATI THERAPEUTICS | Vertrieb & Marketing | 01.09.2022 |
| KITE PHARMA INC | Vertrieb & Marketing | 01.04.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen